Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: email@example.com
Sacituzumab Govitecan Bests Chemotherapy by Improving Progression-Free Survival in HR+ Metastatic Breast CancerMarch 11th 2022
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer achieved statistically significantly improvements in progression-free survival after receiving sacituzumab govitecan.
FDA Approves Abatacept to Proactively Treat Acute Graft-Versus-Host-DiseaseDecember 16th 2021
Abatacept is now available for use in combination with certain immunosuppressants to prevent moderate to severe acute-graft-versus-host disease for select patients who have received unrelated donor hematopoietic stem cell transplant.
Pembrolizumab May Be Associated with Sustainable Relapse-Free Survival in High-Risk MelanomaNovember 8th 2021
After 6 months of additional follow-up, patients with resected high-risk stage II melanoma continued to experience improved relapse-free survival following treatment with adjuvant pembrolizumab.
Sintilimab Plus Chemotherapy Induces Superior Survival in EGFR-Mutated Nonsquamous NSCLCOctober 19th 2021
Sintilimab, a bevacizumab biosimilar injection, met the primary end point of the phase 3 ORIENT-31 trial by significantly increasing progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer.
Axitinib/Pembrolizumab Combination Improves Survival in Metastatic RCC, But Only MarginallyOctober 17th 2021
A real-world survival analysis showed that patients with metastatic RCC treated with axitinib plus pembrolizumab did not experience significantly improved survival outcomes compared with patients treated with ipilimumab plus nivolumab.
Pembrolizumab in Addition to Chemo Holds Potential as New SOC in Cervical Cancer Frontline SettingSeptember 22nd 2021
Data presented at the 2021 ESMO Congress suggest that pembrolizumab in addition to chemo with or without bevacizumab may become new standard of care in the frontline setting of cervical cancer treatment.